NIclonex - An orIGInal CovID-19 therapeutIc In Phase 3
Recent studies show that Niclosamide has antiviral effects on COVID-19 and clinical studies are carried out by different study groups and companies in different parts of the world. Niclosamide is an anthelmintic drug that has been approved for over 60 years. Recently, it has been reported in different studies and reviews that it has a potential of use in SARS-CoV infections, but requires high doses due to its low resolution
MP-204 -Topıcal product for the treatment of vıral skın ınfectıons
MP-204 is a best-in-class, topical product in clinical development for the treatment of viral skin infections such as anogenital warts caused by HPV, and has completed its Phase-II clinical trial.
MP-204 demonstrated significant results in the Phase 2 efficacy/safety study. The MP-204 formulation provided a shorter treatment period (3 weeks), a better safety profile, higher patient compliance and a higher level of complete clearance (over 90%) compared to the clinical data of the best alternative therapies.
MP-303 - Topical product for the treatment of Nonmelanoma skin cancers
MP 303 is a first-in-class, topical product in pre-clinical development for the treatment of non-melanoma skin cancer (“NMSC”) such as squamous cell carcinoma (“SCC”), basal cell carcinoma (“BCC”) and actinic keratosis (“AK”) through targeted necrosis and an immunomodulatory action.
MP-4 SerIes - APain Platform / NSAID Technology Platform (“NTP”)
MN has developed a proprietary formulation technology that can be applied to nearly all oral NSAID medications, increasing their peak plasma concentration (Cmax), shortening their time to maximum plasma concentration (Tmax) while providing gastro intestinal protection.
While having a short Tmax is preferential for a fast effect, this usually also causes a faster elimination, so the drug is only active in the therapeutic window for a shorter period of time. MN has solved this issue as well with its NSAID technology platform (“NTP”). NTP will allow for fast, long acting pain relief with diminished side effects.
NTP based diclofenac has completed a CACO-2 cell study and an animal study with significantly superior results compared to the administration of diclofenac alone. Human trials Phase 1, PK study has been sucessfully completed and the finalized FDF has a 3 year stability.
Opix - a completely new MoA for severe paIn
The premise of the opiX technology is that it has a completely new mechanism of action that does not work through the opioid receptors and has none of the side effects associated with opioids and hence does not have an abuse potential and has been proven to be similar or stronger than high dose opioids in well established animal models.
MP-732 - New treatment modalIty for psorIasIs, a chronic skIn dIsease
MP 732, New treatment modality for psoriasis, a chronic skin disease
Antibiotic Resistance & ACNE – Pre-clinical
Acne is a long-term skin condition that occurs when hair follicles become clogged or dead skin cells and oils from the skin become clogged. The skin is covered with tiny holes called hair follicles or pores. Follicles contain sebaceous glands that keep hair and skin moist. During puberty, hormones can cause the skin to make too much oil and stick together with cells inside the follicle, with external dirt or oil. Although acne can affect people of all ages, it is most common among teenagers. Studies on acne show that only 20% of acne is caused by diet and stress, while roughly 80% of the factors are due to genetics. Acne often causes whiteheads, blackheads, or pimples and is most commonly seen on the face, forehead, chest, back, and shoulders. Antibiotic resistance S epidermidis causes endocarditis, septicemia and prosthetic joint infections. MP-555 will be further investigated with these infections, but MP-555 will first be prepared as a fixed dose formulation for the simpler indication, Acne Vulgaris.
MOLFAC A.I. uses custom, action specific computers to run models that learn from existing data of old molecules to produce new ones . Deep learning is a sub-field of machine learning, where models inspired by how our brain works are expressed mathematically, and are learned automatically, continuously from the data. Deep learning is a key enabler of AI powered technologies being developed across the globe. The Company’s application of deep learning is focusing on complex models that help its custom made machine solve pharmaceutical chemistry based problems with human-like super intelligence. The Company’s working code can create unique synthesizable molecules based on the structure of a molecule that is given into the system. Furthermore the new molecules based on a pre-trained model are checked automatically through databases to discard already existing molecules. The current trained model includes hundreds of thousands of molecules and will grow as new molecules are generated and validated by MOLFAC A.I. Thus MOLFAC A.I. will learn and apply and learn some more, having a snowball effect.